HSDD affects 40%-55% of postmenopausal women, often due to hormonal changes, impacting sexual desire and quality of life.

Up until now, women who’d surpassed menopause and were dealing with frustratingly low libido—a.k.a. hypoactive sexual desire ...

The "little pink pill" is now available to even more women. The Food and Drug Administration (FDA) just approved Addyi for postmenopausal women, which makes this the first medication for low sexual ...

Addyi is the first and only FDA-approved, hormone-free pill clinically proven to treat low sexual desire in women RALEIGH, N.C., July 24, 2025 /PRNewswire/ -- Sprout Pharmaceuticals today announced ...

Viagra, the little blue pill, has been a household name for more than a generation. And now women's sexual health is finally ...

On Dec. 15, Sprout Pharmaceuticals received approval to use its pill, Addyi (flibanserin), to treat low sexual desire in ...